for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

TAIKO PHARMACEUTICAL CO LTD

4574.T

Latest Trade

2,920.00JPY

Change

29.00(+1.00%)

Volume

8,600

Today's Range

2,915.00

 - 

2,934.00

52 Week Range

1,611.00

 - 

2,934.00

As of on the Tokyo Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
2,891.00
Open
2,915.00
Volume
8,600
3M AVG Volume
0.79
Today's High
2,934.00
Today's Low
2,915.00
52 Week High
2,934.00
52 Week Low
1,611.00
Shares Out (MIL)
14.22
Market Cap (MIL)
41,500.59
Forward P/E
27.34
Dividend (Yield %)
0.86

Next Event

Q3 2020 Taiko Pharmaceutical Co Ltd Earnings Release

Latest Developments

More

Earth Chemical announces business and capital alliance with Taiko Pharmaceutical Co Ltd

TAIKO PHARMACEUTICAL raises year-end dividend forecast for FY 2015

TAIKO PHARMACEUTICAL raises consolidated full-year outlook for FY 2015

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About TAIKO PHARMACEUTICAL CO LTD

TAIKO PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company. The Company is engaged in three business segments. The Pharmaceutical Product segment is engaged in the manufacturing, sales and export of gastrointestinal drugs under the name SEIROGAN, SEIROGAN TOI-A (sugar coated tablet) and PISHUT. The Infection Control segment is engaged in the planning, development and sales of infection control products, which apply proprietary technique regarding chlorine dioxide gas. The Others segment is engaged in the manufacturing and sales of bath liquid, soap and gardening pyroligneous acid.

Industry

Biotechnology & Drugs

Contact Info

16F, ORIX Hommachi Bldg

1-4-1, Nishihon-machi

Nishi-ku

+81.6.43911110

http://www.seirogan.co.jp

Executive Leadership

Hitoshi Shibata

Chairman of the Board, Representative Director

Takashi Shibata

President, Representative Director

Tomosada Yoshikawa

Senior Managing Director

Atsunori Kato

Executive Director

Masami Moroi

Executive Director

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, JPY)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (JPY)

2017

76.450

2018

77.380

2019

98.994

2020(E)

105.750
Price To Earnings (TTM)
28.00
Price To Sales (TTM)
3.93
Price To Book (MRQ)
2.42
Price To Cash Flow (TTM)
21.33
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
8.32
Return on Equity (TTM)
7.51

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up